Advertisement

Topics

AstraZeneca’s Checkpoint Inhibitor Scores a Win in Lung Cancer After Last Week’s Failure

12:05 EDT 31 Jul 2017 | Labiotech.eu

Despite a crisis of confidence in AstraZeneca last week, its checkpoint inhibitor, Imfinzi, just got FDA endorsement in NSCLC. Just last week, AstraZeneca saw its stock value drop by 15% — a hit to the market cap that equates to ...

This awesome article AstraZeneca’s Checkpoint Inhibitor Scores a Win in Lung Cancer After Last Week’s Failure appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: AstraZeneca’s Checkpoint Inhibitor Scores a Win in Lung Cancer After Last Week’s Failure

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca’s Checkpoint Inhibitor Scores a Win in Lung Cancer After Last Week’s Failure"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...